Drug Profile
Research programme: AMP-activated protein kinase stimulants - Connexios/Boehringer Ingelheim
Alternative Names: AMPK activators - Connexios; CNX-012; CNX-012-570; CNX-570Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Connexios Life Sciences
- Developer Boehringer Ingelheim; Connexios Life Sciences
- Class Small molecules
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Germany
- 28 Jul 2018 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in India
- 06 May 2014 Preclinical trials in Type-2 diabetes mellitus in Germany (unspecified route)